Cargando…

ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan

BACKGROUND: Early identification of autism spectrum disorder, intellectual developmental disorder, attention-deficit/hyperactivity disorder, and other neurodevelopmental disorders/problems is crucial, yet diagnosis is often delayed for years under the often misguided “wait-and-see” paradigm. The ear...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatakenaka, Yuhei, Fernell, Elisabeth, Sakaguchi, Masahiko, Ninomiya, Hitoshi, Fukunaga, Ichiro, Gillberg, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951052/
https://www.ncbi.nlm.nih.gov/pubmed/27478377
http://dx.doi.org/10.2147/NDT.S108411
_version_ 1782443634340134912
author Hatakenaka, Yuhei
Fernell, Elisabeth
Sakaguchi, Masahiko
Ninomiya, Hitoshi
Fukunaga, Ichiro
Gillberg, Christopher
author_facet Hatakenaka, Yuhei
Fernell, Elisabeth
Sakaguchi, Masahiko
Ninomiya, Hitoshi
Fukunaga, Ichiro
Gillberg, Christopher
author_sort Hatakenaka, Yuhei
collection PubMed
description BACKGROUND: Early identification of autism spectrum disorder, intellectual developmental disorder, attention-deficit/hyperactivity disorder, and other neurodevelopmental disorders/problems is crucial, yet diagnosis is often delayed for years under the often misguided “wait-and-see” paradigm. The early symptomatic syndromes eliciting neurodevelopmental clinical examinations-questionnaire (ESSENCE-Q) is a brief (12-item) screening questionnaire developed specifically for the purpose of speeding up the identification process of a wide variety of neurodevelopmental problems. The aims were to 1) estimate the reliability of the ESSENCE-Q, 2) evaluate the clinical cutoff levels suggested by the author of the ESSENCE-Q, and 3) propose optimal cutoff levels based on receiver operating characteristic analysis. METHODS: The ESSENCE-Q was used for 1 year by a psychiatrist in Kochi, Japan, assessing children under the age of 6 years referred for developmental problems. The children were also clinically assessed with regard to whether or not they met criteria for a developmental disorder (diagnosis positive and diagnosis negative groups). We contrasted the results of the ESSENCE-Q and those of clinical diagnostic assessments in 130 cases. RESULTS: Cronbach’s alpha was 0.82, sensitivity was 0.94 (95% confidence interval [CI]: [0.88, 0.98]), and specificity 0.53 (95% CI: [0.28, 0.77]), which are reasonable psychometrics for a first-step screening tool. Based on receiver operating characteristic analysis, we recommended an optimal cutoff level of yes ≥2 or maybe/a little ≥3 on the ESSENCE-Q (0.87 (95% CI: [0.79, 0.92]) sensitivity and 0.77 (95% CI: [0.50, 0.93]) specificity). CONCLUSION AND IMPLICATION: The ESSENCE-Q can be a good instrument for use as a screening tool for aiding in the process of early identification of neurodevelopmental disorders in clinical settings. To establish the broader validity and reliability of the ESSENCE-Q, case–control studies and general population studies of children in different age groups are needed.
format Online
Article
Text
id pubmed-4951052
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49510522016-07-29 ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan Hatakenaka, Yuhei Fernell, Elisabeth Sakaguchi, Masahiko Ninomiya, Hitoshi Fukunaga, Ichiro Gillberg, Christopher Neuropsychiatr Dis Treat Original Research BACKGROUND: Early identification of autism spectrum disorder, intellectual developmental disorder, attention-deficit/hyperactivity disorder, and other neurodevelopmental disorders/problems is crucial, yet diagnosis is often delayed for years under the often misguided “wait-and-see” paradigm. The early symptomatic syndromes eliciting neurodevelopmental clinical examinations-questionnaire (ESSENCE-Q) is a brief (12-item) screening questionnaire developed specifically for the purpose of speeding up the identification process of a wide variety of neurodevelopmental problems. The aims were to 1) estimate the reliability of the ESSENCE-Q, 2) evaluate the clinical cutoff levels suggested by the author of the ESSENCE-Q, and 3) propose optimal cutoff levels based on receiver operating characteristic analysis. METHODS: The ESSENCE-Q was used for 1 year by a psychiatrist in Kochi, Japan, assessing children under the age of 6 years referred for developmental problems. The children were also clinically assessed with regard to whether or not they met criteria for a developmental disorder (diagnosis positive and diagnosis negative groups). We contrasted the results of the ESSENCE-Q and those of clinical diagnostic assessments in 130 cases. RESULTS: Cronbach’s alpha was 0.82, sensitivity was 0.94 (95% confidence interval [CI]: [0.88, 0.98]), and specificity 0.53 (95% CI: [0.28, 0.77]), which are reasonable psychometrics for a first-step screening tool. Based on receiver operating characteristic analysis, we recommended an optimal cutoff level of yes ≥2 or maybe/a little ≥3 on the ESSENCE-Q (0.87 (95% CI: [0.79, 0.92]) sensitivity and 0.77 (95% CI: [0.50, 0.93]) specificity). CONCLUSION AND IMPLICATION: The ESSENCE-Q can be a good instrument for use as a screening tool for aiding in the process of early identification of neurodevelopmental disorders in clinical settings. To establish the broader validity and reliability of the ESSENCE-Q, case–control studies and general population studies of children in different age groups are needed. Dove Medical Press 2016-07-14 /pmc/articles/PMC4951052/ /pubmed/27478377 http://dx.doi.org/10.2147/NDT.S108411 Text en © 2016 Hatakenaka et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Hatakenaka, Yuhei
Fernell, Elisabeth
Sakaguchi, Masahiko
Ninomiya, Hitoshi
Fukunaga, Ichiro
Gillberg, Christopher
ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan
title ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan
title_full ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan
title_fullStr ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan
title_full_unstemmed ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan
title_short ESSENCE-Q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south Japan
title_sort essence-q – a first clinical validation study of a new screening questionnaire for young children with suspected neurodevelopmental problems in south japan
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951052/
https://www.ncbi.nlm.nih.gov/pubmed/27478377
http://dx.doi.org/10.2147/NDT.S108411
work_keys_str_mv AT hatakenakayuhei essenceqafirstclinicalvalidationstudyofanewscreeningquestionnaireforyoungchildrenwithsuspectedneurodevelopmentalproblemsinsouthjapan
AT fernellelisabeth essenceqafirstclinicalvalidationstudyofanewscreeningquestionnaireforyoungchildrenwithsuspectedneurodevelopmentalproblemsinsouthjapan
AT sakaguchimasahiko essenceqafirstclinicalvalidationstudyofanewscreeningquestionnaireforyoungchildrenwithsuspectedneurodevelopmentalproblemsinsouthjapan
AT ninomiyahitoshi essenceqafirstclinicalvalidationstudyofanewscreeningquestionnaireforyoungchildrenwithsuspectedneurodevelopmentalproblemsinsouthjapan
AT fukunagaichiro essenceqafirstclinicalvalidationstudyofanewscreeningquestionnaireforyoungchildrenwithsuspectedneurodevelopmentalproblemsinsouthjapan
AT gillbergchristopher essenceqafirstclinicalvalidationstudyofanewscreeningquestionnaireforyoungchildrenwithsuspectedneurodevelopmentalproblemsinsouthjapan